Notify me when AWM Investment Company, Inc. files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 102 | $1,035,562,110 | +$143,278,758 | -$108,532,414 | +$34,746,344 | LASR, ADMA, VICR, BKSY, AEHR | 13F-HR | 13 Feb 2026, 16:14 |
| Q3 2025 | 102 | $1,066,683,365 | +$119,927,687 | -$167,236,857 | -$47,309,170 | AEHR, MASS, AMSC, BKSY, AVAV | 13F-HR | 13 Nov 2025, 13:54 |
| Q2 2025 | 94 | $891,745,340 | +$71,014,112 | -$138,302,891 | -$67,288,779 | AMSC, BKSY, ADMA, MASS, AVAV | 13F-HR | 14 Aug 2025, 16:21 |
| Q1 2025 | 95 | $726,032,982 | +$116,265,445 | -$47,797,459 | +$68,467,986 | ADMA, AMSC, AIOT, MASS, ASPI | 13F-HR | 15 May 2025, 14:10 |
| Q4 2024 | 87 | $820,896,060 | +$62,186,202 | -$161,220,829 | -$99,034,627 | ADMA, AMSC, AIOT, BKSY, PI | 13F-HR | 14 Feb 2025, 19:34 |
| Q3 2024 | 98 | $825,431,851 | +$127,292,176 | -$142,948,065 | -$15,655,889 | ADMA, PI, AMSC, ASPN, DXLG | 13F-HR | 14 Nov 2024, 16:01 |
| Q2 2024 | 99 | $740,246,820 | +$60,800,800 | -$103,785,739 | -$42,984,939 | ADMA, AMSC, PI, DXLG, ASPN | 13F-HR | 14 Aug 2024, 10:53 |
| Q1 2024 | 115 | $763,579,402 | +$61,735,114 | -$91,534,513 | -$29,799,399 | PI, ADMA, AMSC, ASPN, DXLG | 13F-HR | 15 May 2024, 17:40 |
| Q4 2023 | 110 | $760,177,632 | +$80,521,439 | -$64,639,767 | +$15,881,672 | DXLG, ASPN, AEHR, Turtle Beach Corp. @0 pre-fund, PI | 13F-HR | 14 Feb 2024, 16:19 |
| Q3 2023 | 108 | $677,527,753 | +$55,942,474 | -$87,427,355 | -$31,484,881 | AEHR, DXLG, VIQ Solutions @1.39 1/21/23-7/, ADMA, PI | 13F-HR | 14 Nov 2023, 16:59 |
| Q2 2023 | 112 | $736,931,467 | +$76,522,617 | -$149,432,857 | -$72,910,240 | AEHR, DXLG, VIQ Solutions @1.39 1/21/23-7/, PI, ARBE | 13F-HR | 11 Aug 2023, 16:19 |
| Q1 2023 | 119 | $735,838,518 | +$79,122,543 | -$98,766,012 | -$19,643,469 | DXLG, TA, PI, AEHR, VIQ Solutions @1.39 1/21/23-7/ | 13F-HR | 12 May 2023, 16:04 |
| Q4 2022 | 121 | $693,532,439 | +$67,049,388 | -$48,836,775 | +$18,212,613 | DXLG, PI, AEHR, TA, ADMA | 13F-HR | 14 Feb 2023, 17:26 |
| Q3 2022 | 122 | $657,671,000 | +$40,365,274 | -$44,740,981 | -$4,375,707 | DXLG, PI, TA, AEHR, CDMO | 13F-HR | 14 Nov 2022, 14:50 |
| Q2 2022 | 119 | $634,774,000 | +$64,124,327 | -$42,633,262 | +$21,491,065 | DXLG, PI, TA, PFSW, VERU | 13F-HR | 12 Aug 2022, 17:30 |
| Q1 2022 | 116 | $776,707,000 | +$31,248,148 | -$34,582,463 | -$3,334,315 | DXLG, NPTN, TA, PI, Zealand Pharma A/S (Denmark) | 13F-HR | 13 May 2022, 16:02 |
| Q4 2021 | 118 | $996,917,000 | +$56,127,975 | -$53,818,822 | +$2,309,153 | DXLG, PI, CDMO, TA, INFU | 13F-HR | 11 Feb 2022, 17:45 |
| Q3 2021 | 119 | $1,019,056,000 | +$150,159,949 | -$88,603,520 | +$61,556,429 | DXLG, Zealand Pharma A/S (Denmark), OPRX, TA, RGEN | 13F-HR | 15 Nov 2021, 14:48 |
| Q2 2021 | 121 | $1,013,230,000 | +$147,895,813 | -$61,522,453 | +$86,373,360 | Zealand Pharma A/S (Denmark), INFU, CDMO, OPRX, LOVE | 13F-HR | 13 Aug 2021, 11:03 |
| Q1 2021 | 110 | $895,114,000 | +$120,982,676 | -$177,512,824 | -$56,530,148 | Zealand Pharma A/S (Denmark), INFU, GNSS, PI, OPRX | 13F-HR | 13 May 2021, 11:32 |
| Q4 2020 | 98 | $787,003,000 | +$83,580,767 | -$79,477,949 | +$4,102,818 | INFU, Zealand Pharma A/S (Denmark), AMSC, GNSS, ARGX | 13F-HR | 12 Feb 2021, 15:13 |
| Q3 2020 | 86 | $610,468,000 | +$68,602,998 | -$104,696,514 | -$36,093,516 | GNSS, Zealand Pharma A/S (Denmark), INFU, ARGX, OPRX | 13F-HR | 12 Nov 2020, 18:08 |
| Q2 2020 | 87 | $570,578,000 | +$64,551,749 | -$84,428,835 | -$19,877,086 | Zealand Pharma A/S (Denmark), GNSS, INFU, LPSN, OOMA | 13F-HR | 13 Aug 2020, 16:35 |
| Q1 2020 | 86 | $376,447,000 | +$50,161,319 | -$76,630,353 | -$26,469,034 | INFU, Zealand Pharma A/S (Denmark), LPSN, BLU, GNSS | 13F-HR | 15 May 2020, 11:14 |
| Q4 2019 | 86 | $511,816,000 | +$62,600,563 | -$94,140,667 | -$31,540,104 | LPSN, Zealand Pharma A/S (Denmark), INFU, NPTN, OOMA | 13F-HR | 13 Feb 2020, 16:04 |
| Q3 2019 | 88 | $471,277,000 | +$43,597,791 | -$56,482,906 | -$12,885,115 | LPSN, Zealand Pharma A/S (Denmark), LIQT, GNSS, IOTS | 13F-HR | 12 Nov 2019, 14:50 |
| Q2 2019 | 92 | $522,976,000 | +$55,592,408 | -$69,918,173 | -$14,325,765 | Zealand Pharma A/S (Denmark), LPSN, IOTS, OPRX, LIQT | 13F-HR | 08 Aug 2019, 12:46 |
| Q1 2019 | 85 | $508,091,000 | +$32,284,573 | -$87,963,673 | -$55,679,100 | LPSN, Zealand Pharma A/S (Denmark), CEVA, OPRX, LOVE | 13F-HR | 14 May 2019, 16:21 |
| Q4 2018 | 85 | $459,470,000 | +$61,791,153 | -$64,099,782 | -$2,308,629 | LPSN, OOMA, Zealand Pharma A/S (Denmark), KIDS, CEVA | 13F-HR | 13 Feb 2019, 13:59 |
| Q3 2018 | 89 | $604,904,000 | +$40,333,303 | -$63,599,136 | -$23,265,833 | LPSN, OPRX, OOMA, CORI, CEVA | 13F-HR | 09 Nov 2018, 16:14 |
| Q2 2018 | 91 | $599,036,000 | +$89,482,551 | -$117,908,552 | -$28,426,001 | LPSN, CEVA, TCMD, KOPN, OOMA | 13F-HR | 09 Aug 2018, 13:57 |
| Q1 2018 | 91 | $518,610,000 | +$63,319,821 | -$50,538,482 | +$12,781,339 | LPSN, CORI, CEVA, KOPN, UCTT | 13F-HR | 10 May 2018, 11:14 |
| Q4 2017 | 94 | $515,304,000 | +$65,566,315 | -$59,382,949 | +$6,183,366 | CEVA, LPSN, CORI, KOPN, UCTT | 13F-HR | 13 Feb 2018, 16:41 |
| Q3 2017 | 89 | $572,573,000 | +$45,722,099 | -$78,987,392 | -$33,265,293 | CEVA, KOPN, LPSN, CORI, SQNS | 13F-HR | 14 Nov 2017, 14:54 |
| Q2 2017 | 92 | $565,534,000 | +$111,994,928 | -$136,374,055 | -$24,379,127 | CEVA, SQNS, KOPN, PI, LPSN | Restatement | 30 Aug 2017, 15:10 |
| Q1 2017 | 96 | $534,711,000 | $0 | $0 | $0 | CEVA, KOPN, AQMS, SQNS, LMAT | New Holdings | 06 Jun 2017, 09:49 |
| Q1 2017 | 97 | $535,008,000 | +$46,324,623 | -$88,622,613 | -$42,297,990 | CEVA, KOPN, AQMS, SQNS, LMAT | 13F-HR | 12 May 2017, 16:51 |
| Q4 2016 | 100 | $510,025,000 | +$61,127,080 | -$85,677,175 | -$24,550,095 | CEVA, NPTN, LMAT, AQMS, KOPN | 13F-HR | 02 Feb 2017, 15:39 |
| Q3 2016 | 99 | $543,134,000 | +$70,715,555 | -$70,337,548 | +$378,007 | CEVA, NPTN, VTAE, VCRA, Brightcove, Inc. | 13F-HR | 14 Nov 2016, 13:43 |
| Q2 2016 | 96 | $468,004,000 | +$34,512,287 | -$134,088,504 | -$99,576,217 | CEVA, VCRA, NPTN, SAAS, Brightcove, Inc. | 13F-HR | 09 Aug 2016, 13:15 |
| Q1 2016 | 93 | $476,438,000 | +$47,829,950 | -$72,625,911 | -$24,795,961 | CEVA, NPTN, PFSW, VCRA, LMAT | 13F-HR | 05 May 2016, 16:21 |
| Q4 2015 | 94 | $508,537,000 | +$35,711,087 | -$95,027,131 | -$59,316,044 | VCRA, CEVA, NPTN, PFSW, LMAT | 13F-HR | 08 Feb 2016, 13:02 |
| Q3 2015 | 118 | $516,330,000 | +$55,258,726 | -$348,821,356 | -$293,562,630 | VCRA, PFSW, ADEP, CEVA, KOPN | 13F-HR | 12 Nov 2015, 16:36 |
| Q2 2015 | 131 | $697,698,000 | +$53,827,551 | -$180,339,780 | -$126,512,229 | XEBEC Adsorption @.45C 11/1/15, PFSW, VCRA, CEVA, KOPN | 13F-HR | 12 Aug 2015, 16:24 |
| Q1 2015 | 136 | $723,199,000 | +$89,575,296 | -$125,179,438 | -$35,604,142 | XEBEC Adsorption @.45C 11/1/15, CEVA, VCRA, PFSW, KOPN | 13F-HR | 08 May 2015, 14:24 |
| Q4 2014 | 139 | $733,432,000 | $0 | $0 | $0 | XEBEC Adsorption @.45C 11/1/15, PFSW, VCRA, CEVA, KOPN | 13F-HR | 11 Feb 2015, 13:25 |